Metformin costs about four dollars for a month’s supply. It has been prescribed to diabetics since 1957. It is one of the most studied drugs in the history of medicine. And according to researchers at the Université de Montréal, it may hold the key to exposing and destroying the hidden reservoirs where HIV survives despite decades of antiretroviral therapy.
The study, published in iScience and led by Petronela Ancuta at the CRCHUM research center, found that metformin does something no current HIV drug was designed to do: it forces the virus out of hiding and pins it to the surface of infected cells like a flag, making it visible to the immune system for the first time.
How a Diabetes Drug Finds HIV
HIV’s survival strategy is concealment. The virus integrates into CD4 T lymphocytes –the very immune cells meant to fight infection –and goes dormant. Antiretroviral therapy can suppress active replication, but it cannot touch the reservoir of silently infected cells. This is why people with HIV must take medication for life. The virus is not gone. It is hiding.
Metformin disrupts this hiding in two ways. First, it inhibits mTOR –a molecular pathway that HIV exploits for replication –slowing the virus’s ability to reproduce. Second, and more significantly, it overexpresses a protein called BST2, which acts as a kind of molecular glue. BST2 traps newly produced viral particles on the surface of infected cells instead of allowing them to escape into the bloodstream.
The result is a cell that is effectively wearing a sign that says “infected.” Neutralizing antibodies can then recognize these flagged cells and direct natural killer cells to destroy them.
Lead author Augustine Fert described the dual mechanism: metformin has “both a proviral and an antiviral effect.” It reactivates enough viral expression to make infected cells visible, while simultaneously preventing the virus from spreading. The researchers found that some antibodies “recognized the virus very well, suggesting their ability to attract and trigger the destruction of infected cells.”
The Shock-and-Kill Strategy
For years, HIV cure research has pursued a concept called “shock and kill” –wake the dormant virus up, then destroy the cells it inhabits. The problem has always been the “shock” part. Most drugs capable of reactivating latent HIV are too toxic, too imprecise, or too expensive for widespread use.
Metformin offers something none of those experimental agents can: a safety profile established over nearly seven decades, a cost measured in cents per pill, and global availability in every pharmacy on earth. It is already prescribed to millions of people, including many who are HIV-positive and also have diabetes or metabolic syndrome.
The study suggests that combining metformin with broadly neutralizing antibodies –several of which are already in clinical development –could create a viable shock-and-kill regimen using existing, affordable tools.
39 Million People Are Waiting
Approximately 39 million people worldwide are living with HIV. The vast majority will take antiretroviral drugs every day for the rest of their lives. The global cost of HIV treatment exceeds $20 billion annually. A functional cure –one that eliminates the reservoir and allows people to stop treatment –would transform the lives of tens of millions and save billions in healthcare costs.
Metformin is not a cure. No one is claiming it is. But it may be a critical piece of the puzzle –the affordable, safe, globally available tool that makes a cure strategy possible.
The Silence Around Cheap Solutions
The pattern is by now familiar. A cheap, off-patent drug shows remarkable potential against a disease that generates billions in annual treatment revenue. The research is published in a peer-reviewed journal. The mechanism is clearly described. The implications are significant.
And then –nothing. No front-page headlines. No emergency funding. No pharmaceutical company racing to run the clinical trial that would confirm whether metformin, at four dollars a month, could help cure a disease that currently requires medications costing thousands.
Is it not worth asking why a study showing that a globally available, pennies-per-dose diabetes drug can expose HIV reservoirs to immune destruction received less media coverage than the latest celebrity scandal? Is the silence a coincidence, or is it the sound of an industry that profits from treatment contemplating what happens when treatment is no longer necessary?
Metformin did not ask for permission to work against HIV. The question is whether anyone with the power to fund a clinical trial will give it the chance to prove what the lab results already suggest.
